Idexx Laboratories (IDXX) Cash from Operations (2009 - 2026)

Idexx Laboratories has reported Cash from Operations for 18 years, with the latest figure at $347.2 million in Q2 2026.

• On a quarterly basis, Cash from Operations rose 86.9% year-over-year to $347.2 million in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 51.41% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 27.21% from the prior year.
• Cash from Operations was $347.2 million for Q2 2026 at Idexx Laboratories, up from $266.2 million in the prior quarter.
• The five-year high for Cash from Operations was $402.3 million in Q3 2025, with the low at $65.8 million in Q2 2022.
• Average Cash from Operations over 5 years is $231.9 million, with a median of $229.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations plunged 71.85% in 2022, then soared 204.2% in 2023.
• Over 5 years, Cash from Operations stood at $173.4 million in 2022, then surged by 44.07% to $249.9 million in 2023, then advanced by 4.87% to $262.0 million in 2024, then jumped by 35.77% to $355.8 million in 2025, then dropped by 2.42% to $347.2 million in 2026.
• The last three Cash from Operations figures came in at $347.2 million (Q2 2026), $266.2 million (Q1 2026), and $355.8 million (Q4 2025), per Business Quant data.